zibotentan and Kidney-Diseases

zibotentan has been researched along with Kidney-Diseases* in 1 studies

Other Studies

1 other study(ies) available for zibotentan and Kidney-Diseases

ArticleYear
Pharmacokinetics and Tolerability of Zibotentan in Patients with Concurrent Moderate Renal and Moderate Hepatic Impairment.
    Clinical pharmacokinetics, 2023, Volume: 62, Issue:12

    Zibotentan, a selective endothelin A receptor antagonist, is in development for chronic liver and kidney disease. The pharmacokinetics (PK) of zibotentan were previously investigated in patients with either renal impairment or hepatic impairment, but the impact of both pathologies on PK was not evaluated. This study evaluated the PK and tolerability of a single oral dose of zibotentan in participants with concurrent moderate renal impairment and moderate hepatic impairment versus control participants.. The presented findings advance the understanding of the PK of zibotentan in both renal impairment and hepatic impairment, with and without overlapping pathologies, and will thus increase the confidence of dose selection in future studies, particularly in vulnerable patient populations with concurrent renal and hepatic impairment.. ClinicalTrials.gov identifier: NCT05112419.

    Topics: Area Under Curve; Humans; Kidney; Kidney Diseases; Liver Diseases; Renal Insufficiency

2023